Efficacy and Safety of 1‐Month Postpartum Zidovudine‐Didanosine to Prevent HIV‐Resistance Mutations after Intrapartum Single‐Dose Nevirapine

Lallemant, Marc; Ngo‐Giang‐Huong, Nicole; Jourdain, Gonzague; Traisaithit, Patrinee; R. Cressey, Tim; Jeannie Collins, Intira; Jarupanich, Tapnarong; Sukhumanant, Thammanoon; Achalapong, Jullapong; Sabsanong, Prapan; Chotivanich, Nantasak; Winiyakul, Narong; Ariyadej, Surabon; Kanjanasing, Annop; Ratanakosol, Janyaporn; Hemvuttiphan, Jittapol; Kengsakul, Karun; Wannapira, Wiroj; Sittipiyasakul, Veerachai; Pornkitprasarn, Witaya; Liampongsabuddhi, Prateung; McIntosh, Kenneth; B. Van Dyke, Russell; M. Frenkel, Lisa; Koetsawang, Suporn; Le Coeur, Sophie; Kanchana, Siripon

doi:10.1086/650745

Public

Efficacy and Safety of 1‐Month Postpartum Zidovudine‐Didanosine to Prevent HIV‐Resistance Mutations after Intrapartum Single‐Dose Nevirapine

Published in Clinical Infectious Diseases • Feb 16, 2010

Authors:

Marc Lallemant

Nicole Ngo‐Giang‐Huong

Gonzague Jourdain

Abstract

BACKGROUND: Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks ...

Subject

Nevirapine

Zidovudine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!